Recent advances in the production of recombinant factor IX: bioprocessing and cell engineering. (3rd April 2023)

• Record Type: Journal Article
• Authors: Beauglehole, Aiden C.; Roche Recinos, Dinora; Pegg, Cassandra L.; Lee, Yih Yean; Turnbull, Victor; Herrmann, Susann; Marcellin, Esteban; Howard, Christopher B.; Schulz, Benjamin L.
• Is Part Of: Critical reviews in biotechnology. Volume 43:Number 3(2023)
• Page Start: 484
• Page End: 502
• Publication Date: 2023-04-03
• Subjects: Chinese hamster ovary cell -- recombinant factor IX -- bioprocessing -- cell engineering -- factor IX production -- post-translational modifications; Biotechnology -- Periodicals; Biotechnology -- Periodicals; Review Literature -- Periodicals; Public Health -- Periodicals; Environment -- Periodicals; Industry -- Periodicals; Biotechnology; Review Literature; Public Health; Environment; Industry; 660.6
• DOI: 10.1080/07388551.2022.2036691
• Languages: English
• ISSNs: 0738-8551

Abstract

Abstract: Appropriate treatment of Hemophilia B is vital for patients' quality of life. Historically, the treatment used was the administration of coagulation Factor IX derived from human plasma. Advancements in recombinant technologies allowed Factor IX to be produced recombinantly. Successful recombinant production has triggered a gradual shift from the plasma derived origins of Factor IX, as it provides extended half-life and expanded production capacity. However, the complex post-translational modifications of Factor IX have made recombinant production at scale difficult. Considerable research has therefore been invested into understanding and optimizing the recombinant production of Factor IX. Here, we review the evolution of recombinant Factor IX production, focusing on recent developments in bioprocessing and cell engineering to control its post-translational modifications in its expression from Chinese Hamster Ovary (CHO) cells.